Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bioventus Inc.BVS · Entity 4996 | Director | June 02, 2026 | June 04, 2026 |
| CONMED CorpCNMD · Entity 4691 | President & CEO | April 01, 2026 | April 02, 2026 |
| MISONIX INCMSON · Entity 132701 | Director | October 29, 2021 | December 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bioventus Inc.
Report date June 02, 2026 · Filed June 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 108,718 |
Reported balance
After 2026-06-02 transaction · row 1
1 source rowRow 1 · 2026-06-02 · Exercise / conversion · Acquired 32,282 · Balance 108,718 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-02 · Exercise / conversion · Disposed 32,282 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2: The RSUs vested on June 2, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 25,146 |
Reported balance
After 2026-06-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-03 · Grant · Acquired 25,146 · Balance 25,146 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F3: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2: The RSUs vested on June 2, 2026.
F3: The RSUs shall vest and become exercisable on the earlier of (i) the day immediately preceding the date of the Issuer's first Annual Meeting of Stockholders following the date of grant and (ii) the first anniversary of the date of grant, subject to the Reporting Person continuing in service on the Issuer's Board of Directors through the applicable vesting date.
CONMED Corp
Report date April 01, 2026 · Filed April 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| RSUs (Restricted Stock Units)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2036-04-01 | Direct | 28,145 |
Reported balance
After 2026-04-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-04-01 · Grant · Acquired 28,145 · Balance 28,145 F1: On March 23rd, 2026, the CONMED Board of Directors approved an additional equity award for the CEO of $1M in target value to be granted in the form of RSUs and scheduled to vest starting April 1st, 2026 over 3-years in three equal annual tranches with a 2-year post-vest holding period to be applied to net after tax shares after each vesting event. |
Filing footnotes · ownership attribution and instrument terms
F1: On March 23rd, 2026, the CONMED Board of Directors approved an additional equity award for the CEO of $1M in target value to be granted in the form of RSUs and scheduled to vest starting April 1st, 2026 over 3-years in three equal annual tranches with a 2-year post-vest holding period to be applied to net after tax shares after each vesting event.
MISONIX INC
Report date October 29, 2021 · Filed December 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-10-29 transaction · row 1
1 source rowRow 1 · 2021-10-29 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger dated as of July 29, 2021 (the "Merger Agreement") among the Issuer, Bioventus Inc. ("Bioventus"), Oyster Merger Sub I, Inc., a Delaware corporation, and a wholly owned subsidiary of Bioventus ("Merger Sub I"), Oyster Merger Sub II, LLC, a Delaware limited liability company, and a wholly owned subsidiary of Bioventus ("Merger Sub II"), under which (a) Merger Sub I merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Bioventus (the "First Merger") and (b) immediately following the consummation of the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving as Misonix, LLC (the "Second Merger" and together with the First Merger, the "Mergers"). F2: Pursuant to the Merger Agreement, at the effective time of the First Merger, each share of Issuer common stock was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of Class A common stock of Bioventus, $0.001 par value per share ("Bioventus Shares"). The disposition was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder. F3: Includes 20,000 options to purchase the Issuer's common stock which, pursuant to the Merger Agreement, at the effective time of the First Merger, automatically vested and thereafter were cancelled and converted into a right to purchase Bioventus Shares on the same terms and conditions that applied to the options immediately prior to the First Effective Time, adjusted by the Option Exchange Ratio (as defined in the Merger Agreement). |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to the Agreement and Plan of Merger dated as of July 29, 2021 (the "Merger Agreement") among the Issuer, Bioventus Inc. ("Bioventus"), Oyster Merger Sub I, Inc., a Delaware corporation, and a wholly owned subsidiary of Bioventus ("Merger Sub I"), Oyster Merger Sub II, LLC, a Delaware limited liability company, and a wholly owned subsidiary of Bioventus ("Merger Sub II"), under which (a) Merger Sub I merged with and into the Issuer, with the Issuer surviving as a wholly-owned subsidiary of Bioventus (the "First Merger") and (b) immediately following the consummation of the First Merger, the Issuer merged with and into Merger Sub II, with Merger Sub II surviving as Misonix, LLC (the "Second Merger" and together with the First Merger, the "Mergers").
F2: Pursuant to the Merger Agreement, at the effective time of the First Merger, each share of Issuer common stock was converted into the right to receive a per share amount (the "Merger Consideration") equal to either an amount in cash equal to $28.00 or 1.6839 validly issued, fully paid and non-assessable shares of Class A common stock of Bioventus, $0.001 par value per share ("Bioventus Shares"). The disposition was exempt from Section 16(b) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 16b-3 promulgated thereunder.
F3: Includes 20,000 options to purchase the Issuer's common stock which, pursuant to the Merger Agreement, at the effective time of the First Merger, automatically vested and thereafter were cancelled and converted into a right to purchase Bioventus Shares on the same terms and conditions that applied to the options immediately prior to the First Effective Time, adjusted by the Option Exchange Ratio (as defined in the Merger Agreement).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2019 Filed Mar 5, 2019 21:27 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionRsus (restricted Stock Units) · Derivative | 675 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-009940 · form4.xml · derivative · entry 6 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 675 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 1999 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts (25%) over a four year period. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:27 UTC | CONMED Corp CNMD · Entity 4691 | GrantOptions To Purchase Common Stock · Derivative | 56,000 | $0.00 Strike: $78.76 | $0.00 |
DisclosureSEC source: 0001127602-19-009940 · form4.xml · derivative · entry 5 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,000 Underlying: Common Stock · 56,000 shares Expires 2029-03-01 F1 · derivative.exercise_date: The stock options were granted under the Company's 2018 Long-Term Incentive Plan and generally vest in equal amounts over a five year period Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:27 UTC | CONMED Corp CNMD · Entity 4691 | Tax withholdingCommon Stock | 341 | $78.76 | $26,857.16 |
DisclosureSEC source: 0001127602-19-009940 · form4.xml · nonDerivative · entry 4 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,423 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:27 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionCommon Stock | 725 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-009940 · form4.xml · nonDerivative · entry 3 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,764 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:27 UTC | CONMED Corp CNMD · Entity 4691 | Tax withholdingCommon Stock | 318 | $78.76 | $25,045.68 |
DisclosureSEC source: 0001127602-19-009940 · form4.xml · nonDerivative · entry 2 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,039 Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 21:27 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionCommon Stock | 675 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-009940 · form4.xml · nonDerivative · entry 1 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:10 UTC | CONMED Corp CNMD · Entity 4691 | GrantOptions To Purchase Common Stock · Derivative | 57,000 | $0.00 Strike: $59.96 | $0.00 |
DisclosureSEC source: 0001127602-18-010030 · form4.xml · derivative · entry 7 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 57,000 shares Expires 2028-03-01 F3 · derivative.exercise_date: The stock options were granted under the Company's 2015 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:10 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionRsus (restricted Stock Units) · Derivative | 725 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-010030 · form4.xml · derivative · entry 6 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,450 Underlying: Common Stock · 725 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2015 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts (25%) over a four year period. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:10 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionRsus (restricted Stock Units) · Derivative | 675 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-010030 · form4.xml · derivative · entry 5 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 675 Underlying: Common Stock · 675 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 1999 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts (25%) over a four year period. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:10 UTC | CONMED Corp CNMD · Entity 4691 | Tax withholdingCommon Stock | 341 | $59.96 | $20,446.36 |
DisclosureSEC source: 0001127602-18-010030 · form4.xml · nonDerivative · entry 4 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,682 Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:10 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionCommon Stock | 725 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-010030 · form4.xml · nonDerivative · entry 3 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,023 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:10 UTC | CONMED Corp CNMD · Entity 4691 | Tax withholdingCommon Stock | 318 | $59.96 | $19,067.28 |
DisclosureSEC source: 0001127602-18-010030 · form4.xml · nonDerivative · entry 2 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,298 Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:10 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionCommon Stock | 675 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-010030 · form4.xml · nonDerivative · entry 1 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,616 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 18:03 UTC | CONMED Corp CNMD · Entity 4691 | GrantOptions To Purchase Common Stock · Derivative | 57,000 | $0.00 Strike: $41.93 | $0.00 |
DisclosureSEC source: 0001127602-17-009975 · form4.xml · derivative · entry 7 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,000 Underlying: Common Stock · 57,000 shares Expires 2027-03-01 F3 · derivative.exercise_date: The incentive stock options ("ISOs") were granted under the Company's 2015 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 18:03 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionRsus (restricted Stock Units) · Derivative | 725 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009975 · form4.xml · derivative · entry 6 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,175 Underlying: Common Stock · 725 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 2015 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts (25%) over a four year period. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 18:03 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionRsus (restricted Stock Units) · Derivative | 675 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009975 · form4.xml · derivative · entry 5 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,350 Underlying: Common Stock · 675 shares Expires 2025-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Each restricted stock unit ("RSU") represents a contingent right to receive one share of common stock, par value $0.01 per share of ConMed Corporation (the "Company") and will be subject to the terms and conditions of the Company's 1999 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts (25%) over a four year period. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 18:03 UTC | CONMED Corp CNMD · Entity 4691 | Tax withholdingCommon Stock | 396 | $41.93 | $16,604.28 |
DisclosureSEC source: 0001127602-17-009975 · form4.xml · nonDerivative · entry 4 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,941 Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 18:03 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionCommon Stock | 725 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009975 · form4.xml · nonDerivative · entry 3 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,337 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 18:03 UTC | CONMED Corp CNMD · Entity 4691 | Tax withholdingCommon Stock | 369 | $41.93 | $15,472.17 |
DisclosureSEC source: 0001127602-17-009975 · form4.xml · nonDerivative · entry 2 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,612 Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 18:03 UTC | CONMED Corp CNMD · Entity 4691 | Exercise / conversionCommon Stock | 675 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-17-009975 · form4.xml · nonDerivative · entry 1 Beyer Pat · CIK 0001627985 · President - International 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.